Xiao Jiani, Zhang Tianxiang, Gao Fei, Zhou Zhengwei, Shu Guang, Zou Yizhou, Yin Gang
Department of Pathology, School of Basic Medical Sciences, Xiangya Hospital, Central South University, Changsha 410000, China.
Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06511, USA.
Cancers (Basel). 2022 Nov 17;14(22):5657. doi: 10.3390/cancers14225657.
As an important component of the innate immune system, natural killer (NK) cells have gained increasing attention in adoptive cell therapy for their safety and efficacious tumor-killing effect. Unlike T cells which rely on the interaction between TCRs and specific peptide-MHC complexes, NK cells are more prone to be served as "off-the-shelf" cell therapy products due to their rapid recognition and killing of tumor cells without MHC restriction. In recent years, constantly emerging sources of therapeutic NK cells have provided flexible options for cancer immunotherapy. Advanced genetic engineering techniques, especially chimeric antigen receptor (CAR) modification, have yielded exciting effectiveness in enhancing NK cell specificity and cytotoxicity, improving in vivo persistence, and overcoming immunosuppressive factors derived from tumors. In this review, we highlight current advances in NK-based adoptive cell therapy, including alternative sources of NK cells for adoptive infusion, various CAR modifications that confer different targeting specificity to NK cells, multiple genetic engineering strategies to enhance NK cell function, as well as the latest clinical research on adoptive NK cell therapy.
作为天然免疫系统的重要组成部分,自然杀伤(NK)细胞因其安全性和有效的肿瘤杀伤作用,在过继性细胞治疗中受到越来越多的关注。与依赖TCR与特定肽-MHC复合物相互作用的T细胞不同,NK细胞由于能够在无MHC限制的情况下快速识别并杀伤肿瘤细胞,更易于作为“现货”细胞治疗产品。近年来,不断涌现的治疗性NK细胞来源为癌症免疫治疗提供了灵活的选择。先进的基因工程技术,尤其是嵌合抗原受体(CAR)修饰,在增强NK细胞特异性和细胞毒性、提高体内持久性以及克服肿瘤衍生的免疫抑制因子方面取得了令人兴奋的效果。在本综述中,我们重点介绍基于NK细胞的过继性细胞治疗的当前进展,包括用于过继输注的NK细胞替代来源、赋予NK细胞不同靶向特异性的各种CAR修饰、增强NK细胞功能的多种基因工程策略,以及过继性NK细胞治疗的最新临床研究。